SAB Biotherapeutics, Inc.
NASDAQ:SABS
2.18 (USD) • At close February 5, 2025
Overzicht | Financiële gegevens
Bedrijfsnaam | SAB Biotherapeutics, Inc. |
Symbool | SABS |
Munteenheid | USD |
Prijs | 2.18 |
Beurswaarde | 20,119,809 |
Dividendpercentage | 0% |
52-weken bereik | 2 - 6.3 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Dr. Eddie Joe Sullivan Ph.D. |
Website | https://www.sabbiotherapeutics.com |
An error occurred while fetching data.
Over SAB Biotherapeutics, Inc.
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies based on human antibodies. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at specific diseases, including infectious diseases comprising COVID-19 and influenza, immune and autoimmune
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)